- Medicine - Mar 28 Imperial blood expert recognised for a lifetime of achievement
- Life Sciences - Mar 28 The OCD Brain: how animal research helps us understand a devastating condition
- Medicine - Mar 28 From synthetic biology to global health challenges
- Medicine - Mar 27 Major genetic study identifies 12 new genetic variants for ovarian cancer
- Medicine - Mar 27 No ’weekend admission effect’ for the elderly sustaining broken hips in the NHS
- Medicine - Mar 27 Half Marathon support extended
- Medicine - Mar 27 World- leading Imaging Centre of Excellence to be officially opened in Glasgow
- Medicine - Mar 24 Designing selective antibiotics can reduce drug resistance, says Nobel laureate
- Medicine - Mar 24 UofG scientists set to lead new era in pancreatic cancer treatment
- Life Sciences - Mar 24 Major breakthrough in the manufacture of red blood cells
- Careers - Mar 23 Oxford University leaders negotiate innovation community research partnerships in China
- Medicine - Mar 23 Flower petal inspired menstrual pads crowned Althea 2017 winner
Ebola vaccine offers long-lasting immunity
An Ebola vaccine has been shown to provide immunity for up to a year after immunisation in all of those immunised in a new study.
The findings, based on a Phase 1 clinical trial involving 75 healthy subjects, were published in the Journal of the American Medical Association (JAMA).
The study was led by the Oxford Vaccine Group at the University of Oxford. It tested the prime-boost Ebola vaccine regimen being developed by Janssen Vaccines & Prevention B.V. that is based on Janssen’s AdVac technology and MVA-BN technology from Bavarian Nordic A/S. Healthy volunteers were given one vaccine dose to prime their immune system, and the alternative vaccine to boost their immune response. Additional Phase 1, 2 and 3 studies are ongoing to build on these findings.
This is the longest duration follow-up for any heterologous prime-boost Ebola vaccine regimen yet published.
Dr Matthew Snape from the Department of Paediatrics at Oxford, who led the research, said: ’The persistence of vaccine-induced immunity to one year post-immunisation is truly impressive.
’The fact that all participants retained Ebola-specific antibodies to the end of the study does raise hope that this vaccine could induce responses that last for several years.
’This study was conducted in a European population, so it’s important to note that immune responses may differ in a sub-Saharan African population, but these vaccine candidates are currently being assessed in this region.
’Additional research is also needed to explore the persistence of immunity beyond the one year mark and the response to booster doses of vaccine.’
A total of ten clinical studies are being conducted on a parallel track across the US, Europe and Africa in support of potential eventual registration for the Ebola vaccine regimen. The first study of the vaccine regimen in a West African country affected by the recent Ebola outbreak began in Sierra Leone in October 2015.
The full research letter, - Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Ankara-Vectored Ebola Vaccines at 1 Year ,’ can be read in JAMA.
Last job offers
- Medicine/Pharmacology - 28.3
Professor / Reader
- Medicine/Pharmacology - 27.3
Chair in Dental Education and Head of Continuing Professional Development
- Medicine/Pharmacology - 24.3
Chair in Ageing
- Medicine/Pharmacology - 15.3
Professorship of Oncological Imaging
- Medicine/Pharmacology - 14.3
Assistant Professor in Reproductive Biology
- Medicine/Pharmacology - 10.3
Chair of Nursing- 56793
- Medicine/Pharmacology - 22.2
Professorship of Clinical Microbiology
- Medicine/Pharmacology - 18.2
Associate Professor in Pharmacy